Search for a trial

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non*Small-Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate overall survival (OS) in the intent-to-treat (ITT) subject population defined by this protocol.Key secondary objectives are to evaluate OS in the epidermal growth factor receptor (EGFR) wild type…

Phase IIIB randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator's choise of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatment

The primairy objective of the trial is to determine the efficacy of BIBW 2992 plus weekly paclitaxel compared to the investigators choise of chemotherapy alone in patients with NSCLC stage IIIb or IV progressing after experiencing a benefit from…

Electrochemotherapy in head and neck cancer patients

The primary objective of this study is to determine the response rate of electrochemotherapy in head and neck cancer. Secondary objectives are to monitor local and systemic side effects and adverse events and to determine quality of life before and…

A prospective double-blind randomized Phase III study of 300 mg vs. 150 mg erlotinib in current smokers with locally advanced or metastatic NSCLC in second-line setting after failure on chemotherapy

To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.

Illness Perceptions in patients with lung cancer

The aim of this research is to gain a more detailed insight into the illness perceptions of patients with lung cancer. With this insight it is our aim to improve biopsychosocial care for these patients. Research question: What are the illness…

A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum-based chemotherapy.

The primary objective of this study is to compare the Overall Survival (OS) of first-linemaintenance therapy with erlotinib versus erlotinib administered at the time of diseaseprogression in patients with histologically documented, advanced or…

Single centre study comparing results of pathologic analysis of EUS-FNA with EUS-TCB in patients with enlarged mediastinal lymph nodes and evaluating mutation analysis on EUS-TCB in patients with NSCLC.

To compare the feasibility of mutation analysis in samples obtained with EUS-FNA and EUS-TCB in patients with mediastinal lymph node metastasis in NSCLC. To compare EUS-TCB with EUS-FNA in diagnosing benign and malignant mediastinal disease.

Stereotactic Radiotherapy for Metastasis to the Lung

To determine whether SRT achieves a local control rate comparable to surgery in patients with metastatic lung disease.

Non invasive imaging of Cetuximab-Zirconium-89 uptake with Positron-Emission-Tomography (PET) scans: A phase I trial in stage IV cancer patients.

To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.

Single centre study comparing results of pathologic analysis of EUS-FNA with EUS-TCB in patients with enlarged mediastinal lymph nodes.

Primary Objective: The primary objective is to investigate whether EUS-TCB had an added value on EUS-FNA alone. Secondary Objective(s): The secondary objective is to study whether EUS-TCB does not have a higher complication rate than EUS-FNA alone.

Determination of the toxicity of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin - vinorelbine for patients with stage III non-small cell lung cancer (NSCLC): a phase I study.

To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine.

High Definition bronchoscopy, an exploratory study of diagnostic value in comparison to standard white light bronchoscopy and autofluorescence bronchoscopy

(1) Investigate diagnostic performance (sensitivity) of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to standard WLB for detecting abnormalities of the tracheobronchial tree. Furthermore we aim to…

A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients with high-risk for recurrence: NVALT- 8B.

The primary aim of the study is to investigate whether adding Nadroparin to adjuvant chemotherapy in patients in the poor prognostic group (i.e. high SUV) prolongs recurrence-free survival.

CT-PET virtual bronchoscopy guided transbronchial needle aspiration for mediastinal lymph node staging in suspected lung cancer

To determine whether CT-PET virtual bronchoscopy guided TBNA (CT-PET-VB guided TBNA) is suitable for staging MLNs in patients with suspected LC.

PET probe guided extirpation of FDG-PET positive lymph nodes which are negative on other imaging modalities in head and neck cancer patients scheduled for primary irradiation

Feasibility of PET probe guided extirpation of FDG-PET positive lymph nodes which are negative on other imaging modalities in head and neck cancer patients scheduled for primary irradiation.

Value of structural psychosocial screening in improving
quality of life and satisfaction with care received in patients with lung
cancer. The "care" study.

The aim is to examine whether care and treatment guided by structural psychosocial screening leads to a better quality of life and greater patient satisfaction than usual care alone in patients with lung cancer.

Prophylactic Cranial Irradiation (PCI) versus observation in radically treated patients with stage III non-small cell lung cancer: A phase III randomized study (NVALT-11/ DLCRG-02).

This randomized phase III study is designed to investigate whether PCI could reduce the incidence of brain metastases or delay their appearance in patients with stage III NSCLC who are treated with curative intention.

Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out if the combination of gemcitabine plus carboplatin and iniparib works better than gemcitabine and carboplatin alone in subjects with stage IV squamous non-small-cell lung cancer (NSCLC) that have not…

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC).

Primary Objective: To compare Overall Survival (OS) of subjects with Stage IV/recurrent NSCLC of squamous histology who have been randomized to ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and…

LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.

Run-in phase I: To confirm the safety and tolerability of BIBF 1120 up to a dose level of 200 mg b.i.d added to a standard dose of cisplatin/gemcitabine in first line NSCLC patients with squamous cell histology. Pharmacokinetics of BIBF 1120 and…